GlaxoSmithKline Research & Development Limited FDA Record

Summary

Related names

Each name below has its own page. Its counts cover only the records FDA filed under that name and are not part of the totals for GlaxoSmithKline Research & Development Limited above.

Recent FDA inspections

4 inspections from Dec 17, 2009 to May 16, 2017.

NAI

No objectionable conditions or practices were found during the inspection.

VAI

Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

OAI

Regulatory and/or administrative actions are recommended.

Look up the inspector observations behind these results with the FDA 483 search, or check for formal enforcement with the FDA warning letter search.

FDA-inspected facilities

1 inspected site, newest inspection first.

GlaxoSmithKline Research & Development Limited and the FDA: common questions

Has GlaxoSmithKline Research & Development Limited received an FDA warning letter?

No FDA warning letter addressed to the name "GlaxoSmithKline Research & Development Limited" is on file. This answer covers that name only: letters addressed to a related company name or to one of its sites are listed on that name's or site's own page.

Has GlaxoSmithKline Research & Development Limited received an FDA Form 483?

FDA has not published a Form 483 for "GlaxoSmithKline Research & Development Limited" in its reading room. FDA publishes some Form 483s, not all of them.

When did the FDA last inspect GlaxoSmithKline Research & Development Limited?

The most recent FDA inspection on file ended May 16, 2017 at Stevenage, United Kingdom and was classified VAI. FDA has 4 inspections of GlaxoSmithKline Research & Development Limited on file.